CHRS Jan 2026 3.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
At close: 10:32AM EDT
| Previous Close | 0.5500 |
| Open | 0.7000 |
| Bid | 0.6000 |
| Ask | 0.7500 |
| Strike | 3.00 |
| Expire Date | 2026-01-16 |
| Day's Range | 0.7000 - 0.7000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.08k |
GlobeNewswireCoherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the anti-programmed cell death protein 1 (PD-1) antibody, toripalimab-tpzi, and other
Simply Wall St.We Think Some Shareholders May Hesitate To Increase Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation
Key Insights Coherus BioSciences to hold its Annual General Meeting on 29th of May Salary of US$982.9k is part of CEO...
Simply Wall St.Coherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Coherus BioSciences ( NASDAQ:CHRS ) First Quarter 2024 Results Key Financial Results Revenue: US$77.1m (up 138% from 1Q...
© 2024 Yahoo. All rights reserved.